67 related articles for article (PubMed ID: 31834627)
21. Galectins in Cancer and the Microenvironment: Functional Roles, Therapeutic Developments, and Perspectives.
Li CH; Chang YC; Chan MH; Yang YF; Liang SM; Hsiao M
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572346
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of serum galectin-1 autoantibodies in seven types of cancer: A potential biomarker.
Nanami T; Hoshino I; Shiratori F; Yajima S; Oshima Y; Suzuki T; Ito M; Hiwasa T; Kuwajima A; Shimada H
Mol Clin Oncol; 2021 Sep; 15(3):179. PubMed ID: 34276998
[TBL] [Abstract][Full Text] [Related]
23. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
[TBL] [Abstract][Full Text] [Related]
24. Clinical and prognostic differences between ALK-negative anaplastic large cell lymphoma and peripheral T cell lymphoma, not otherwise specified: a single institution experience.
Deng XW; Zhang XM; Wang WH; Wang SL; Jin J; Fang H; Ren H; Liu YP; He XH; Dong M; Song YW; Li YX
Ann Hematol; 2016 Aug; 95(8):1271-80. PubMed ID: 27209536
[TBL] [Abstract][Full Text] [Related]
25. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
Savage KJ; Harris NL; Vose JM; Ullrich F; Jaffe ES; Connors JM; Rimsza L; Pileri SA; Chhanabhai M; Gascoyne RD; Armitage JO; Weisenburger DD;
Blood; 2008 Jun; 111(12):5496-504. PubMed ID: 18385450
[TBL] [Abstract][Full Text] [Related]
26. Improving survival of 3760 patients with lymphoma: Experience of an academic center over two decades.
Liu W; Ji X; Song Y; Wang X; Zheng W; Lin N; Tu M; Xie Y; Ping L; Ying Z; Zhang C; Deng L; Wu M; Feng F; Leng X; Sun Y; Du T; Zhu J
Cancer Med; 2020 Jun; 9(11):3765-3774. PubMed ID: 32281275
[TBL] [Abstract][Full Text] [Related]
27. High intratumoural galectin-1 expression predicts adverse outcome in ALK
Holst JM; Ludvigsen M; Hamilton-Dutoit SJ; Bendix K; Plesner TL; Nørgaard P; Møller MB; Steiniche T; Rabinovich GA; d'Amore F; Pedersen MB
Hematol Oncol; 2020 Feb; 38(1):59-66. PubMed ID: 31834627
[TBL] [Abstract][Full Text] [Related]
28. Expression of cytotoxic proteins in peripheral T-cell and natural killer-cell (NK) lymphomas: association with extranodal site, NK or Tgammadelta phenotype, anaplastic morphology and CD30 expression.
Kanavaros P; Boulland ML; Petit B; Arnulf B; Gaulard P
Leuk Lymphoma; 2000 Jul; 38(3-4):317-26. PubMed ID: 10830738
[TBL] [Abstract][Full Text] [Related]
29. Update on the Treatment of Anaplastic Large Cell Lymphoma.
Vu K; Ai W
Curr Hematol Malig Rep; 2018 Apr; 13(2):135-141. PubMed ID: 29516333
[TBL] [Abstract][Full Text] [Related]
30. Anaplastic large cell lymphoma, ALK-negative.
Ferreri AJ; Govi S; Pileri SA; Savage KJ
Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
[TBL] [Abstract][Full Text] [Related]
31. Primary cutaneous Ki-1(CD30) positive anaplastic large cell lymphoma in childhood.
Tomaszewski MM; Moad JC; Lupton GP
J Am Acad Dermatol; 1999 May; 40(5 Pt 2):857-61. PubMed ID: 10321635
[TBL] [Abstract][Full Text] [Related]
32. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
Shea L; Mehta-Shah N
Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
[TBL] [Abstract][Full Text] [Related]
33.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
34.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]